CN104640866B - 用作脂肪酸合成酶抑制剂的氢吡咯并吡咯衍生物 - Google Patents

用作脂肪酸合成酶抑制剂的氢吡咯并吡咯衍生物 Download PDF

Info

Publication number
CN104640866B
CN104640866B CN201380049347.9A CN201380049347A CN104640866B CN 104640866 B CN104640866 B CN 104640866B CN 201380049347 A CN201380049347 A CN 201380049347A CN 104640866 B CN104640866 B CN 104640866B
Authority
CN
China
Prior art keywords
cancer
compound
bases
refer
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380049347.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104640866A (zh
Inventor
W.施特勒
C.察克拉基迪斯
B.吕特纳
D.温克
F.乔德纳
A.韦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN104640866A publication Critical patent/CN104640866A/zh
Application granted granted Critical
Publication of CN104640866B publication Critical patent/CN104640866B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380049347.9A 2012-09-24 2013-08-30 用作脂肪酸合成酶抑制剂的氢吡咯并吡咯衍生物 Expired - Fee Related CN104640866B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12006668 2012-09-24
EP12006668.3 2012-09-24
PCT/EP2013/002606 WO2014044356A1 (en) 2012-09-24 2013-08-30 Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors

Publications (2)

Publication Number Publication Date
CN104640866A CN104640866A (zh) 2015-05-20
CN104640866B true CN104640866B (zh) 2017-06-06

Family

ID=47088611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380049347.9A Expired - Fee Related CN104640866B (zh) 2012-09-24 2013-08-30 用作脂肪酸合成酶抑制剂的氢吡咯并吡咯衍生物

Country Status (16)

Country Link
US (1) US9416133B2 (https=)
EP (1) EP2897958B1 (https=)
JP (1) JP6259460B2 (https=)
KR (1) KR20150061644A (https=)
CN (1) CN104640866B (https=)
AR (1) AR092211A1 (https=)
AU (1) AU2013320636A1 (https=)
BR (1) BR112015005862A2 (https=)
CA (1) CA2885673A1 (https=)
ES (1) ES2608040T3 (https=)
HK (1) HK1210470A1 (https=)
IL (1) IL237839A0 (https=)
MX (1) MX2015003542A (https=)
RU (1) RU2015115278A (https=)
SG (1) SG11201502014XA (https=)
WO (1) WO2014044356A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
BR112017026682A2 (pt) * 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002770A1 (en) * 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
CN101384596A (zh) * 2006-02-15 2009-03-11 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CN101472584A (zh) * 2006-04-07 2009-07-01 詹森药业有限公司 用作组胺h4受体调节剂的吲哚类和苯并咪唑类
CN101668746A (zh) * 2007-03-01 2010-03-10 詹森药业有限公司 作为组胺h3受体调节剂的四氢异喹啉化合物
WO2011048018A1 (en) * 2009-10-19 2011-04-28 Boehringer Ingelheim International Gmbh Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
WO2011056635A1 (en) 2009-10-27 2011-05-12 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2012064642A1 (en) 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP3190108B1 (en) * 2011-03-08 2021-05-19 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384596A (zh) * 2006-02-15 2009-03-11 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CN101472584A (zh) * 2006-04-07 2009-07-01 詹森药业有限公司 用作组胺h4受体调节剂的吲哚类和苯并咪唑类
CN101668746A (zh) * 2007-03-01 2010-03-10 詹森药业有限公司 作为组胺h3受体调节剂的四氢异喹啉化合物
WO2009002770A1 (en) * 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
WO2011048018A1 (en) * 2009-10-19 2011-04-28 Boehringer Ingelheim International Gmbh Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use

Also Published As

Publication number Publication date
US9416133B2 (en) 2016-08-16
HK1210470A1 (en) 2016-04-22
KR20150061644A (ko) 2015-06-04
WO2014044356A1 (en) 2014-03-27
CN104640866A (zh) 2015-05-20
MX2015003542A (es) 2015-07-17
BR112015005862A2 (pt) 2017-07-04
AR092211A1 (es) 2015-04-08
SG11201502014XA (en) 2015-04-29
JP6259460B2 (ja) 2018-01-10
ES2608040T3 (es) 2017-04-05
RU2015115278A (ru) 2016-11-20
EP2897958A1 (en) 2015-07-29
EP2897958B1 (en) 2016-09-21
CA2885673A1 (en) 2014-03-27
US20150252046A1 (en) 2015-09-10
AU2013320636A1 (en) 2015-05-07
IL237839A0 (en) 2015-05-31
JP2015529229A (ja) 2015-10-05

Similar Documents

Publication Publication Date Title
CN104640866B (zh) 用作脂肪酸合成酶抑制剂的氢吡咯并吡咯衍生物
JP6333450B2 (ja) （アザ−）イソキノリノン誘導体
AU2013218357B2 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
JP6097820B2 (ja) ピロロトリアジノン誘導体
JP6096879B2 (ja) 二環式ピラジノン誘導体
JP6417415B2 (ja) １，３−二置換シクロペンタン誘導体
CN105008329B (zh) 作为fasn抑制剂的哌嗪衍生物
JP6377732B2 (ja) １，３−ジアミノシクロペンタンカルボキサミド誘導体
CN104797553B (zh) 3‑氨基环戊烷甲酰胺衍生物
CN105612157B (zh) 3-取代的环戊基胺衍生物
HK1209106B (en) (aza-)isoquinolinone derivatives
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210470

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170606

Termination date: 20190830

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1210470

Country of ref document: HK